KINDER HOLDING CORP

Inactive Instrument

Press Releases Kinder Holding Corp OTC Bulletin Board

Equities

US4945261067

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	23-02-08	AQ
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	22-11-09	AQ
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	22-09-28	AQ
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	22-05-12	AQ
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	22-02-08	AQ
NEXIEN BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	22-01-21	AQ
NEXIEN BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	21-11-22	AQ
NEXIEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	21-10-12	AQ
NEXIEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	21-05-05	AQ
Nexien BioPharma, Inc. Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services	21-02-19	GL
NEXIEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	21-02-11	AQ
NEXIEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION (form 10-Q)	20-11-10	AQ
NEXIEN BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	20-09-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer